Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NeuroRx Initiates Study for Breakthrough Therapy Targeting Suicidal Bipolar Depression | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

NeuroRx Initiates Study for Breakthrough Therapy Targeting Suicidal Bipolar Depression

Will test oral antidepressant, NRX-101, in maintaining remission from Severe Bipolar Depression

By: Cassandra Gervolino

NeuroRx, Inc announced that it has initiated a pivotal Phase 2b/3 study for NRX-101 for the treatment of patients with Severe Bipolar Depression and Acute Suicidal Ideation and Behavior (ASIB). 
 
NRX-101 has been granted Breakthrough Therapy Designation and Fast Track Designation by the U.S. FDA. The drug is designed to address bipolar depression with suicidal ideation, an indication for which there is no currently approved drug and for which the only FDA-approved treatment remains electroconvulsive therapy (ECT).
 
“We are delighted to initiate this study of patients suffering from Severe Bipolar Depression and ASIB at JPS Health Network (JPS) in Fort Worth, Texas.  NeuroRx is addressing a life-threatening condition that kills 25,000 Americans each year and for which the only currently approved therapy is ECT, with its known complications.  This study is the first to test a potentially life-saving alternative for patients with an unmet medical need.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters